Back to "A 3-P MACE event occurred in 83 patients..."
Strong Support
quantitative
Analysis v3
History

For adults with diabetes who do not have advanced artery disease, taking evolocumab for five years lowers the chance of having a first heart attack, stroke, or other major cardiovascular event by 2.1...

80
Pro
0
Against

Mechanism

Synthesis from 1 study

How it works

This drug stops a protein from removing LDL receptors from the liver, so the liver can pull more bad cholesterol out of the blood. With less cholesterol circulating, less of it builds up in artery walls, which prevents blockages from forming and reduces the risk of heart attacks and strokes.

Most probable mechanism

In Simple Terms

A drug blocks a protein that normally removes LDL receptors from the liver, so more receptors stay on the liver surface to pull LDL cholesterol out of the blood. With less LDL in the blood, less fat builds up in artery walls, which prevents new blockages from forming and lowers the chance of heart attacks and strokes.

Causal chain
1

A monoclonal antibody binds to and neutralizes PCSK9 protein in the bloodstream

Verified by multiple studies
which leads to
2

Neutralized PCSK9 cannot bind to LDL receptors on hepatocytes, preventing their degradation

Verified by multiple studies
which leads to
3

LDL receptors are recycled to the hepatocyte membrane instead of being broken down in lysosomes

Verified by multiple studies
which leads to
4

Increased LDL receptor density on hepatocytes enhances clearance of LDL particles from plasma

Verified by multiple studies
which leads to
5

Sustained reduction in plasma LDL cholesterol decreases lipid deposition into the arterial intima

Verified by multiple studies
which leads to
6

Reduced lipid accumulation slows initiation and progression of atherosclerotic lesions in arterial walls

Verified by multiple studies
which leads to
7

Stabilization of nascent plaques and reduced plaque burden lowers the likelihood of thrombotic occlusion leading to myocardial infarction, ischemic stroke, or revascularization

Verified by multiple studies

Evidence from Studies

Supporting (1)

80

Community contributions welcome

80

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

Randomized Controlled Trial
Human

Contradicting (0)

0

Community contributions welcome

No contradicting evidence found

Gold Standard Evidence Needed

According to GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this specific claim, ordered from strongest to weakest evidence.

Sign up to see full verdict

Source Study

Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes

Score: 80
DOI: 10.1001/jama.2026.3277

Similar Assertions

In adults with diabetes who do not have advanced artery disease, a medication called evolocumab lowers the risk of dying from any cause over five years compared to a placebo.

80
0
94%

In adults with diabetes who do not have advanced artery disease, the drug evolocumab lowers the chance of having a heart attack, stroke, or needing a procedure to restore blood flow over five years, compared to a placebo.

80
0
93%

In adults with diabetes who do not have advanced artery disease, a medication called evolocumab lowers the chance of having a heart attack, stroke, or needing a procedure to restore blood flow over five years.

80
0
89%

For people with diabetes or clogged arteries who haven’t had a heart attack or stroke yet, taking a drug called evolocumab every two weeks can lower their chance of having a first heart attack, stroke, or heart-related death by about 25% over nearly 5 years.

90
0
88%

In adults with diabetes who do not have advanced artery disease, a medication called evolocumab is associated with a reduction in the risk of death from any cause over five years, from 10.1% to 7.8%.

80
0
87%